Advertise with us
Clinical Group

Global Journal of Cancer Therapy


    • Volume/IssueClick here
    • Review ProcessDouble Blind
      • Publication lead time3 - 4 weeks
      • Indexing statusYes; Purview
      • Manuscript Processing ChargesClick here
      • Submission ChargesNo
      • Waiver policy for APCYes
      • Language of Full TextEnglish
      • Full-text formats availablePDF, HTML
    • Show +
    • Type of LicenseCreative Commons
    • Open AccessYes; Policy
      • Does the author retain unrestricted copyright?Yes
      • Does the author retain publishing rights?Yes
      • Permanent article identifierDOI (Digital Object Identifier)
    • Show +
    • NamePeertechz Publications Inc.,
      10880 Wilshire Blvd., Los Angeles, California, 90024, USA
    • Show +


    M.Waheed Roomi
    M.Waheed Roomi

    Dr. Rath Research Institute, 1260 Memorex Drive, Santa Clara, USA

    Tel: (408)730-4481
    Fax: (408) 588-7174

    More Info.

    Welcome note

    From the desk of

    Dr. Tsuyoshi Shirakawa, MD.

    Executive Editor,

    Global Journal of Cancer Therapy

    Welcome to our website! I am very happy for your visit.

    Global Journal of Cancer Therapy reports both clinical and experimental results related to cancer, and is using online review and Editorial Manager System for quality review process. The Journal invites all type of clinical and medical case reports, case studies, basic researches, clinical images, pharmacology and nursing, as it were, total oncology. The goal of us is to keep a record of the state-of-the-art research or case report and to promote study, research and improvement within its various specialties, then to develop total oncology.

    We believe your expertise knowledge will help in the growth of the journal and as well help many budding research scientists all around the world. Your article will be a key insight into real medical cases that are essential for physicians, and may ultimately help to improve patient outcomes.

    Executive Editors

    Tsuyoshi Shirakawa
    Office Doctor
    Department of Medicine
    Kyushu University

    After I graduated from Kyushu University Graduate School of Medical Sciences in 2004, I started junior residency at Kyushu Medical Center and Kyushu University hospital from 2004 to 2006. Next, I worked as a senior resident at Kyushu Cancer Center hospital in 2006. Then, I researched about cancer stem cells at Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science.
    I got Diplomate, Subspeciality Board of Medical Oncology in 2012, and worked as a chief resident National Cancer Center Hospital, Tokyo. At National Cancer Center Hospital, I researched about esophageal cancer chemotherapy mainly.
    Then, I joined and worked at the department of Gastrointestinal and Clinical Oncology Division of Kyushu Cancer Center Hospital from 2013 to 2015. From 2015 to 2017, I was a head of Oncology division of Miyazaki Prefectural Miyazaki Hospital, and a main and leading member of Kyushu Medical Oncology Group and Kyushu-Yamaguchi Total Oncology Group, respectively. Now in 2018, I work in Karatsu Higashi-matsuura Medical Association Center as a doctor of internal medicine.

    Research Interest:

    Medical Oncology (Mainly Gastrointestinal Cancer), Cancer stem cell (Basic research), Palliative medicine, General Medicine, Gastroenterology, Clinical study, Multi-disciplinary coordination and multi-disciplinary study.


    Original articles
    Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation. Rinsho Ketsueki. 2006 Oct;47(10):1372-6.

    A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol (2014) 74:1207-15, DOI 10.1007/s00280-014-2597-3.

    Improvement in the awareness of palliative care nursing using STAS-J in an acute care hospital. J Palliat Care Med 2015, 5:3

    Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. Anti-Cancer Drugs. 2016 Oct; 27(9): 891-8.

    Analysis of a questionnaire survey regarding current conditions against exposure to anticancer drugs and reports of cancer chemotherapy at outpatient departments in Japan. Pharmacology & Pharmacy, 2017, 8, 140-152.

    Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. Exp Cell Res. 2012 Sep 10;318(15):1799-807.

    Human STEAP3 maintains tumor growth under hypoferric condition. Exp Cell Res. 2011 Nov 1;317(18):2582-91.

    Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases. Anticancer research 2014, 34: 215-220.

    Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan. Anticancer research 2014, 34: 2035-2040.

    Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan.
    Anti-Cancer Drugs 2016, 27(5): 457-63.

    Efficacy and Safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Research 2016 Apr; 36(4): 1959-66.

    Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol, 2016 Jul 15 DOI 10.1007/s00280-016-3106-7.

    Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer. 2017 May 11 DOI: 10.1007/s10120-017-0725-6.

    Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemotherapy Pharmacology, 2017 Jun 26. DOI 10.1007/s00280-017-3371-0.

    Irinotecan mnotherapy as third-line or later treatment in advanved gastric cancer. Gastric Cancer, 21(3), 464-472 DOI 10.1007/s10120-017-0759-9.

    Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. Anticancer Drugs, 2017 Sep 12 DOI 10.1097/CAD.0000000000000562.

    Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer. Anticancer Res. 2017 Nov;37(11):6459-6468.

    Corresponding author
    Successful chemoradiotherapy for neuroendocrine tumor grade 3 arising from the mandibular gingiva: a case report and literature review. Open Journal of clinical & medical case report, Volume 2 (2016) Issue 5: 1089.

    Case reports
    A complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report. Molecular and Clinical Oncology 2017 Jul; 7(1): 93-97.

    Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body: a case report. J Med Case Rep. 2012, 6:315.

    Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review. Int canc conf J. 2012 Oct DOI10.1007/s13691-012-0060-z.

    Successful Chemoradiotherapy for undifferentiated malignant neoplasm arising from the left pulmonary artery Case Rep Oncol 2014;7:484-490.

    Successful multimodal therapy for undifferentiated carcinoma with neuroendocrine differentiation in the clival region. Int canc conf J. 2014 July DOI 10.1007/s13961-014-0179-1.

    Anti-HER2 combination chemotherapy for advanced gastric cancer associated with the Peutz-Jeghers syndrome: a case report and literature review. Int canc conf J. 2013 Nov DOI 10.1007/s13961-013-0139-1.

    Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis. Molecular and Clinical Oncology 5: 579-582, 2016.

    More Info.

    Editorial Board Join as Editor

    Esteban Orenes-Pinero
    Associated Professor
    Deparmenr of Biochemistry & Molecular Biology
    Universidad de Murcia

    Research Interest: Current Professional Activity: Fibrilación Auricular, Miocardiopatía Hipertrófica, Micrornas,Remodelado Cardíaco

    More Info.
    Raj Kumar Koiri
    Assistant Professor
    Department of Zoology
    Dr. Hari Singh Gour Central University

    Research Interest: To study the metabolic adaptation for survival occurring in the cancer cells

    More Info.
    Jinbo Gao
    Department of Gastrointestinal Surgery
    Huazhong University of Science and Technology

    Research Interest:  Gastric Cancer; Colon Cancer; Rectal Cancer; Interferon Regulatory Factor-1 (IRF-1); Chemotherapy; Drug Resistance; Telomerase

    More Info.
    Gang Du
    Shanghai Jiaotong University
    Research Interest: Clinical Tumour Classification And Diagnosis, Data Mining In Healthcare, Clinical Pathway Modeling, Simulation And Scheduling Optimization, Decision-Making In Healthcare  
    More Info.
    Mirela Sedic
    Assistant Professor
    Department of Biotechnology
    University of Rijeka

    Research Interest: Her Major Scientific Interests Include Cancer Biology And Treatment, With Particular Emphasis On Sphingolipid Signalling In Cancer.

    More Info.
    Maryam Azimi Mohammadabadi
    Department of Immunology
    Tehran University of Medical Science

    Research Interest: Potential Therapeutic Applications of Arteether, a Semi-Synthetized Derivative of Artemisinin on a Murine Model of Breast Cancer. As a Result, I Have Got Some Experience Atan Area of Tumor Immunology/Immunotherapynamed "Chemoimmunotherapy". Chemoimmunotherapy is an Approach for the Treatment of Cancers in Whichthe Focus is to enhance the Efficacy of chemotherapeutic Agents by Concomitant Application of Compounds with Immunomodulatory Properties. Besides my Thesis Work, I Managed to Do a Course in Cellular Immunology with Professor Hassan, One of the Well-Knownimmunologists in Iran, so that i could also Work on Cellular Immunology Aspects of Tumors. Moreover, Considering the Reported Associations between Molecular Players such as CTLA-4, PDL-1 and also Different Micrornas in Tumor Progression, i am Currently Planning to further Study these Associations in order to improve the Efficacy of Tumor Immunotherapy

    More Info.
    Francisco Torrens
    Associated Professor
    Deparmenr of Biochemistry & Molecular Biology
    Universidad de Murcia,

    Research Interest: Theoretical Chemistry, Physical Chemistry, Mathematical Chemistry, Computational Chemistry, Molecular Modelling, Simulation, And Design, Computer-Aided Drug Design And Development, Molecular Graphics And Representation Of Molecular Properties.

    More Info.
    Tsuyoshi Shirakawa
    Department of Oncology
    Miyazaki University Hospital

    Research Interest: Medical Oncology (Mainly Gastrointestinal Cancer), Cancer Stem Cell, Palliative Medicine,Multi-Disciplinary Coordination And Multi-Disciplinary Study

    More Info.
    View more

    Video Endoscopic Inguinal Lymphadenectomy: Refi ning surgical technique after ten years experience

    Published On: December 30, 2017 | Pages: 034 - 037

    Author(s): Marcos Tobias-Machado, Pericles Rios Auad*, Victor Corona, Igor Silva, Oseas de Castro Neves, Eliney Ferreira Faria, Pablo Matos, Alexandre Cesar Santos, Roberto Machado, Aurus Dourado and Hamilton de Campos Zampolli
    Abstract View Full Article View DOI: 10.17352/gjct.000021

    Role of tumor heterogeneity in drug resistance

    Published On: July 20, 2017 | Pages: 032 - 033

    Author(s): Dhruv Kumar*
    Abstract View Full Article View DOI: 10.17352/gjct.000020

    MEK Inhibitors in Combination with Immune Checkpoint Inhibition: Should we be Chasing Colorectal Cancer or the KRAS Mutant Cancer

    Published On: May 26, 2017 | Pages: 030 - 031

    Author(s): Julius Strauss*
    Abstract View Full Article View DOI: 10.17352/gjct.000019

    Angiosarcoma of the Scalp and Face: A Hard to Treat Tumor

    Published On: April 15, 2017 | Pages: 026 - 029

    Author(s): Jmour Omar*, Kochbati Lotfi , Ghith Sahar and Benna Farouk
    Abstract View Full Article View DOI: 10.17352/gjct.000018

    The Promise of Disease Management in Greece

    Published On: March 30, 2017 | Pages: 018 - 025

    Author(s): Konstantinos Stamatiou, Richard Lacroix, Eleni Almpani, Konstantinos Katsanos, Georgios Tzitzikos and Maria Saridi*
    Abstract View Full Article View DOI: 10.17352/gjct.000017

    Abrikossoff’s Tumour Mimicking a Neoplastic Tumour of the Breast: A Case Report

    Published On: March 20, 2017 | Pages: 015 - 017

    Author(s): Alassiri A*, Al Ali A, Vaysse C, Escourrou G, Vinet B and Rimailho J
    Abstract View Full Article View DOI: 10.17352/gjct.000016

    The Role of Decavanadate in Anti- Tumour Activity

    Published On: March 11, 2017 | Pages: 012 - 014

    Author(s): M Aureliano*
    Abstract View Full Article View DOI: 10.17352/gjct.000015

    Diagnosing HPV-Related Oropharyngeal Cancers: The Need to Speak a Common Language

    Published On: March 07, 2017 | Pages: 008 - 011

    Author(s): Daniela Russo#, Francesco Merolla#, Gennaro Ilardi*, Silvia Varricchio, Danila Caroppo, Virginia Napolitano, Massimo Mascolo and Stefania Staibano
    Abstract View Full Article View DOI: 10.17352/gjct.000014

    Is it Time for the Introduction of Colostomy Free Survival in Rectal Cancer Patients

    Published On: February 28, 2017 | Pages: 004 - 007

    Author(s): Mostafa El Haddad*
    Abstract View Full Article View DOI: 10.17352/gjct.000013

    Primary Spindle Cell Rhabdomyosarcoma of Prostate: A Case Report with Review of Literature

    Published On: February 10, 2017 | Pages: 001 - 003

    Author(s): Ram Nawal Rao*, Sanjay Kannaujia and Paramita Paul
    Abstract View Full Article View DOI: 10.17352/gjct.000012

    Google Ads

    Peertechz @Social

    Peertechz Tweets

    Case Reports

    Pinterest on GJCT